Eli Lilly's Cyramza fuels expansion quest with positive bladder cancer showing

Lilly is working to expand Cyramza, which hauled in more than $614 million in worldwide 2016 sales.

Eli Lilly’s had mixed results in its quest to expand cancer blockbuster hopeful Cyramza. But the data from its latest attempt, this time in bladder cancer, look good.

Wednesday, the Indianapolis drugmaker announced that a phase 3 study of the med in urothelial carcinoma patients had met its primary endpoint, significantly beating out placebo on the progression-free survival front. And that leaves the door open for an FDA approval down the line.

Lilly wouldn’t mind the extra indication; right now, it boasts nods in metastatic non-small cell lung cancer, advanced stomach cancer and metastatic colorectal cancer that helped rake in $614.1 million in sales last year. And trials of the med in liver cancer and breast cancer have come up short.


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

RELATED: The gang's all here: Merck's Keytruda nabs I-O's third bladder cancer approval this month

Bladder cancer, of course, won’t necessarily be an easy arena to enter, considering the presence of five checkpoint inhibitors—four of which won their approvals in the last few months—in the space. Roche’s Tecentriq picked up the first nod last May, and since then, Bristol-Myers Squibb’s Opdivo, AstraZeneca’s Imfinzi, Pfizer and Merck KGaA’s Bavencio, and Merck’s Keytruda have followed with green lights of their own.

RELATED: Roche’s shocking Tecentriq fail raises red flag for bladder cancer rivals

By the time Cyramza, a VEGF med, gets there, though, there’s a chance the field may not be as crowded. Tecentriq’s fate, for one, is hanging in the balance after the med earlier this month failed to prove it could actually prolong patients' lives. That flop put its approval in jeopardy, and Bristol, AZ and the Pfizer/Merck KGaA team—all of whom are still waiting for their own overall survival data—on notice.

With that in mind, Lilly “anticipates that overall survival results are likely to be required for global regulatory submissions,” it said, and it expects final data in that department to arrive in the middle of next year.

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.